NewAmsterdam Pharma raises €160m Series A funding co-led by Forbion, Morningside Ventures and Ascendant BioCapital

– NETHERLANDS, Naarden –  NewAmsterdam Pharma, a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, today announced the completion of a €160M Series A funding round co-led by Forbion Capital Partners, Morningside Ventures, and Ascendant BioCapital alongside Kaiser Foundation Hospitals, BVF Partners L.P.,…

Inversago Pharma appoints Dr. Carlo Incerti to its Board as Chairman along with raising US$35m Series B financing led by Forbion

– CANADA, Montreal –  Inversago Pharma Inc., the peripheral CB1 blockade company, today announced it has secured a US$35 million Series B financing round led by Forbion, with co-investment from the Fonds de solidarité FTQ, and strong participation from existing investors Genesys, JDRF T1D Fund, Amorchem, Anges Québec Capital, adMare BioInnovations and angels.…